Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 23
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Agios Pharmaceuticals Inc
AGIO
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$37.19
0.01
0.03%
Ult. Agg.: Oct 22, 4:00 PM
$37.19
0.01
0.03%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Utili:
I risultati di Q3 2026 tra 14 giorni da adesso in gio nov 5th, prima dell'apertura del mercato
Agios Pharmaceuticals Financials
Agios Pharmaceuticals (AGIO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Agios Pharmaceuticals Q2 EPS $(1.69) Misses $(1.67) Estimate, Sales $44.745M Beat $25.521M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.67) by 1.2 percent. This is a 12.44 percent increase over losses of $(1.93) per share
Benzinga Newsdesk
Earnings Scheduled For April 29, 2026
Benzinga Insights
PRO
Agios Pharmaceuticals Q1 EPS $(1.69) Beats $(1.79) Estimate, Sales $20.746M Beat $13.646M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which beat the analyst consensus estimate of $(1.79) by 5.59 percent. This is a 9.03 percent decrease over losses of $(1.55) per share
Benzinga Newsdesk
Earnings Summary: Agios Pharmaceuticals Q4
Benzinga Insights
PRO
Agios Pharmaceuticals Q4 EPS $(1.86) Beats $(1.94) Estimate, Sales $19.967M Beat $12.014M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.86) per share which beat the analyst consensus estimate of $(1.94) by 3.93 percent. This is a 4.12 percent increase over losses of $(1.94) per share
Benzinga Newsdesk
Earnings Scheduled For February 12, 2026
Benzinga Insights
